Oracle Buys goBalto
Oracle today announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
goBalto’s study startup solutions are activated at over 90,000 research sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30 percent quantifiable reduction in study startup cycle times.
Today, Oracle Health Sciences offers customers the industry's most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.
“Clinical trial site selection and activation is one of the most manual and time-consuming processes for our customers,” said Steve Rosenberg, Senior Vice President and General Manager of Oracle Health Sciences Global Business Unit. “Oracle Health Sciences is designed to provide the industry with the best end-to-end clinical trial experience and the addition of goBalto will further allow our customers to remove another barrier from delivering treatments to patients faster.”
“We set out on a mission to streamline the clinical trial study startup process ten years ago because we saw how untenable it was for pharmaceutical companies and contract research organizations to track 1,000+ sites by 1,000+ specialists on spreadsheets,” said Jae Chung, Founder and President of goBalto.
“We are delighted to join forces with Oracle as the benefits offered to both our customers and employees as a broader clinical trial continuum are unparalleled in the industry,” said Sujay Jadhav, CEO of goBalto.
More information about this announcement is available at www.oracle.com/gobalto.
Contact Info
Deborah Hellinger
Oracle Corporate Communications
+1.212.508.7935
deborah.hellinger@oracle.com
Ken Bond
Oracle Investor Relations
+1.650.607.0349
ken.bond@oracle.com
About Oracle
The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia. For more information about Oracle (NYSE:ORCL), please visit us at www.oracle.com.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
